Advertisement
New Zealand markets close in 2 hours 27 minutes

  • NZX 50

    11,754.57
    -81.47 (-0.69%)
     

  • NZD/USD

    0.5859
    -0.0046 (-0.79%)
     

  • NZD/EUR

    0.5513
    -0.0032 (-0.58%)
     

  • ALL ORDS

    7,755.90
    -143.00 (-1.81%)
     

  • ASX 200

    7,503.70
    -138.40 (-1.81%)
     

  • OIL

    85.85
    +3.12 (+3.77%)
     

  • GOLD

    2,426.00
    +28.00 (+1.17%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,177.46
    -208.41 (-1.27%)
     

  • NIKKEI 225

    36,808.73
    -1,270.97 (-3.34%)
     

  • NZD/JPY

    90.0940
    -1.1600 (-1.27%)
     

Teva to Present New Data for Fremanezumab

Sarah Collins
Updated
Teva to Present New Data for Fremanezumab

Today, Teva Pharmaceutical Industries (TEVA) announced that it will present new data for its migraine drug Fremanezumab, which is under review by the FDA for the preventive treatment as a monthly or quarterly injection, at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The event is being held from June 28 to July 1. Teva plans to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab.

Continue reading